Prosensa to Appoint Michael Wyzga to Supervisory Board

Prosensa to Appoint Michael Wyzga to Supervisory Board  Leiden, The Netherlands, April 8, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, today announced that Michael S. Wyzga has been nominated for appointment to its Supervisory Board at the next shareholders' meeting, scheduled for June 17, 2014.  "We welcome Michael  as an  instrumental addition to  our Supervisory  Board,"  said  Hans  Schikan,  Prosensa's  CEO.  "Michael's  extensive  financial  and  transactional expertise will support the company significantly in our  efforts  to bring  much-needed, life-saving  treatments for  rare genetic  diseases  to  patients. His  long-term  tenure  at  Genzyme,  one  of  the  most  successful  companies in  the  rare disease  space,  will  be invaluable  as  we  continue  developing therapies for  boys with Duchenne  muscular dystrophy and  building  our company."  Mr. Wyzga most  recently served as  President and Chief  Executive Officer  of  Radius Health. Prior to joining Radius, Mr. Wyzga was Executive Vice President and Chief Financial  Officer of  Genzyme Corporation until  its $20.1  billion  acquisition by  Sanofi in  April 2011.  He  joined Genzyme  in 1998  and  held  primary responsibility for the  company's financial management worldwide.  Mr.  Wyzga currently serves on the board of directors for OncoMed  Pharmaceuticals,  Akebia Therapeutics and Idenix Pharmaceuticals.  "Michael's corporate leadership experience in rare diseases makes him an ideal fit for Prosensa, and his contribution will  be vital as the company works  to  successfully advance  its DMD  drug pipeline,"  said David  Mott, Chairman  of  Prosensa's Supervisory Board.  "I am pleased to join Prosensa at  such a significant moment in the  company's  history and  look  forward  to  working  alongside  a  world-class  team  with  exceptional leadership in rare diseases," said Michael Wyzga. "It is an  honor  to be able to share my experience  and contribute to the future direction  and  growth of a  company working so  diligently to find  a therapeutic option  for  boys with this devastating disease."  Notes to editors  About Prosensa Holding N.V.  Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Its primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy (DMD), myotonic dystrophy and Huntington's disease.  Prosensa's current portfolio includes six compounds for the treatment of DMD, all of which have received orphan drug status in the United States and the European Union. The compounds use an innovative technique called exon-skipping to provide a personalized medicine approach to treat different populations of DMD patients.  CONTACT: Prosensa Holding N.V.          Celia Economides, Senior Director, IR & Corporate Communications          Phone: +1 917 941 9059          Email:  Prosensa Holding B.V. Logo  
Press spacebar to pause and continue. Press esc to stop.